Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.
about
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionHistoplasmosis: a clinical and laboratory updatecontinuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysisEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theAntifungal clinical trials and guidelines: what we know and do not knowLiposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy erasIncidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic CriteriaTherapy of systemic fungal infections.Combination therapy for mucormycosis: why, what, and how?Gastrointestinal histoplasmosis.Liposomal amphotericin B: clinical experience and perspectives.Histoplasmosis: a review for clinicians from non-endemic areas.Improvements in diagnosis of histoplasmosis.An update on the use of antifungal agents.Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Fungal infections in intensive care unit: challenges in diagnosis and managementCurrent options in antifungal pharmacotherapy.Antifungal therapies in the intensive care unit.Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realizedTreatment of endemic mycoses.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Amphotericin B use in children: conventional and lipid-based formulations.Management of fungal lung disease in the immunocompromised.Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review.Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review.Comparison between liposomal formulations of amphotericin B.Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.Histoplasmosis in transplant recipients.Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center.[Disseminated histoplasmosis in Rio Grande do Sul].
P2860
Q24187699-84154F96-DCCE-45E6-B9FB-D8B5242DAA63Q24675642-1915D11B-6E71-45E5-9249-76EB7C6E05DBQ28534551-15ED3EB1-BD26-45E5-B675-4BCF16E2D2C8Q30240770-E4B9FDFD-D4E2-46DC-BEAB-675F1B441234Q33753500-FD830295-794C-4216-A7A2-D418CDB3D078Q34212799-FCE73F09-FC6D-4310-8995-CF035FB6A8A4Q34400255-C0993797-CB4E-4464-9C30-3C7646B284E5Q34960317-87BE0BBA-01EE-4FAE-AC69-F851C9164D1CQ35494596-465916A4-3C24-4C92-9535-29477DBF0EAFQ35860053-3E55A10B-05B4-45AB-A79E-09DC5B9BC389Q35967453-84A1FB9F-F663-41BB-A4C8-0B47028F8D8CQ35974333-084C36A5-1FDB-4FA5-92E2-23F42C2B8288Q36011779-DD317FAD-E148-40F1-A201-CB2AFEF8DE0BQ36140647-FFAEC220-F557-43A3-9D34-F953873E51C4Q36511359-8883401B-F104-4688-82B9-0E99C66BFA85Q36627264-CCAF97F2-8892-4C1A-B9E9-061D1D8629D1Q36724783-7A0F0429-E65F-4763-80E2-11014D938B51Q36868273-4D7FA3EF-894E-43C2-863B-645C6C467B92Q37058527-2572ECBA-152C-4AEA-A080-8F0842070442Q37151326-41F2FB34-6DE5-4271-8005-CFF17DCD674CQ37161793-F20372B5-1CEF-4158-A640-092AB1A16673Q37164085-8C53804C-1A12-4B19-9DD5-F29F9FF602A7Q37393668-B489031F-54BB-49A9-AC08-7B669E44322CQ37729998-6217EFAD-5B43-43E8-909F-14C606973897Q37816399-99631030-E08B-4A2B-9986-E27733F72CA0Q37854727-7028C66E-07DE-4C17-90C5-6024FAD4A569Q37909774-ABE4C01D-B1D6-4D50-A813-1E86E234180AQ38077678-32C3F62C-383E-4EC0-A892-EEAEC541F735Q38079194-3AB734CB-C623-4A3C-A6DD-11C6B93BCBE9Q38085729-3B1968D8-C312-4FC6-A599-46C1A2BB88C7Q38195802-483E24F5-1F8F-420F-AA3B-1F196E06934CQ38696930-9F17796B-87DF-4573-B1F3-279BE7AF5A56Q38848844-8F9AEB86-E306-40C1-9BC0-7930FA0AFAB5Q38872275-ABF752C0-CDA4-4A96-84DF-531FC00377D2Q40043040-FC1CCA4A-8F54-49B5-ADB3-A11C662D0EFBQ40043530-6D3D57A6-7ADE-44B8-8162-AA8226BC623EQ40175242-3D8A4A7A-9ABC-4AFF-BB6E-B1ADE8524466Q40222438-DE48DFBD-20E1-442B-85A0-11AFD29BF117Q40489588-6A514FDE-4748-43C3-B23E-CEEAAEB5C927Q40513117-4439CD19-9245-4E79-9CBA-D0B87EE913AE
P2860
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@en
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@nl
type
label
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@en
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@nl
prefLabel
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@en
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@nl
P2093
P1476
Safety and efficacy of liposom ...... asmosis in patients with AIDS.
@en
P2093
Carol A Kauffman
Dan Lancaster
David M Bamberger
Gretchen A Cloud
Mitchell Goldman
Philip C Johnson
Richard Hafner
U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group
William E Dismukes
William G Powderly
P304
P356
10.7326/0003-4819-137-2-200207160-00008
P407
P577
2002-07-01T00:00:00Z